MINNEAPOLIS, March 02, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced that management will participate in the following upcoming investor conferences:
The 33rd Oppenheimer Annual Healthcare Conference, which is being held virtually from March 13th-15th.
The Sidoti Small-Cap Conference, which is being held virtually from March 22nd-23rd.
Live audio webcasts of the presentations will be accessible under the “Events & Webcasts” section of the Company's investor relations website at http://investors.tactilemedical.com. Archives of the webcasts will be available for replay following each conference.
About Tactile Medical
Tactile Medical is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at home. The company collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall healthcare costs and improve the quality of life for tens of thousands of patients each year.

| Last Trade: | US$15.77 | 
| Daily Change: | 0.70 4.64 | 
| Daily Volume: | 821,401 | 
| Market Cap: | US$351.510M | 
 November 03, 2025  | |

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load